{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T16:36:07Z","timestamp":1766507767458,"version":"3.48.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"DOI":"10.1182\/bloodadvances.2025016659","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T19:09:41Z","timestamp":1757444981000},"page":"6246-6251","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Progressive NK-cell dysfunction and ILC imbalance favor immune evasion in multiple myeloma"],"prefix":"10.1182","volume":"9","author":[{"given":"Maria Teresa","family":"Bilotta","sequence":"first","affiliation":[{"name":"1Innate Lymphoid Cells Unit, Immunology Research Area, Bambino Ges\u00f9 Children's Hospital IRCCS, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2293-9698","authenticated-orcid":false,"given":"Antonio Giovanni","family":"Solimando","sequence":"additional","affiliation":[{"name":"2Guido Baccelli Unit of Internal Medicine, Department of Precision and Regenerative Medicine and Ionian Area-(DiMePRe-J), School of Medicine, University of Bari Aldo Moro, Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1942-2601","authenticated-orcid":false,"given":"Vanessa","family":"Desantis","sequence":"additional","affiliation":[{"name":"3Pharmacology Section, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro Medical School, Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3737-9837","authenticated-orcid":false,"given":"Lucia","family":"Di Marzo","sequence":"additional","affiliation":[{"name":"3Pharmacology Section, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro Medical School, Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Sabatini","sequence":"additional","affiliation":[{"name":"1Innate Lymphoid Cells Unit, Immunology Research Area, Bambino Ges\u00f9 Children's Hospital IRCCS, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1831-2569","authenticated-orcid":false,"given":"Sergio","family":"Forcelloni","sequence":"additional","affiliation":[{"name":"1Innate Lymphoid Cells Unit, Immunology Research Area, Bambino Ges\u00f9 Children's Hospital IRCCS, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1806-2584","authenticated-orcid":false,"given":"Alessandro","family":"Andriano","sequence":"additional","affiliation":[{"name":"2Guido Baccelli Unit of Internal Medicine, Department of Precision and Regenerative Medicine and Ionian Area-(DiMePRe-J), School of Medicine, University of Bari Aldo Moro, Bari, Italy"},{"name":"3Pharmacology Section, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro Medical School, Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arcangelo","family":"Morizio","sequence":"additional","affiliation":[{"name":"4Orthopedics and Traumatology Unit Azienda Ospedaliera Universitaria Consorziale Policlinico \u201cGiovanni XXIII,\u201d Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Argentiero","sequence":"additional","affiliation":[{"name":"5Medical Oncology Unit, IRCCS Istituto Tumori \"Giovanni Paolo II,\" Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1515-0090","authenticated-orcid":false,"given":"Roberto","family":"Ria","sequence":"additional","affiliation":[{"name":"2Guido Baccelli Unit of Internal Medicine, Department of Precision and Regenerative Medicine and Ionian Area-(DiMePRe-J), School of Medicine, University of Bari Aldo Moro, Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6994-2595","authenticated-orcid":false,"given":"Linda","family":"Quatrini","sequence":"additional","affiliation":[{"name":"1Innate Lymphoid Cells Unit, Immunology Research Area, Bambino Ges\u00f9 Children's Hospital IRCCS, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4658-1747","authenticated-orcid":false,"given":"Lorenzo","family":"Moretta","sequence":"additional","affiliation":[{"name":"6Tumor Immunology Unit, Bambino Ges\u00f9 Children's Hospital Istituto di Ricerca e Cura a Carattere Scientifico, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0757-0108","authenticated-orcid":false,"given":"Paola","family":"Vacca","sequence":"additional","affiliation":[{"name":"1Innate Lymphoid Cells Unit, Immunology Research Area, Bambino Ges\u00f9 Children's Hospital IRCCS, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3773-8829","authenticated-orcid":false,"given":"Nicola","family":"Tumino","sequence":"additional","affiliation":[{"name":"1Innate Lymphoid Cells Unit, Immunology Research Area, Bambino Ges\u00f9 Children's Hospital IRCCS, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"issue":"1","key":"2025122309411406300_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"2025122309411406300_bib2","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3389\/fonc.2020.00636","article-title":"Deregulation of adaptive T cell immunity in multiple myeloma: insights into mechanisms and therapeutic opportunities","volume":"10","author":"Leblay","year":"2020","journal-title":"Front Oncol"},{"issue":"suppl 2","key":"2025122309411406300_bib3","first-page":"S4","article-title":"The immune system in multiple myeloma and precursor states: lessons and implications for immunotherapy and interception","volume":"98","author":"Dhodapkar","year":"2023","journal-title":"Am J Hematol"},{"key":"2025122309411406300_bib4","doi-asserted-by":"crossref","first-page":"100870","DOI":"10.1016\/j.mam.2020.100870","article-title":"NK cells and ILCs in tumor immunotherapy","volume":"80","author":"Sivori","year":"2021","journal-title":"Mol Aspects Med"},{"issue":"5","key":"2025122309411406300_bib5","doi-asserted-by":"crossref","first-page":"2052658","DOI":"10.1080\/21645515.2022.2052658","article-title":"Anti CD38 monoclonal antibodies for multiple myeloma treatment","volume":"18","author":"Gozzetti","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"2025122309411406300_bib6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat Cancer"},{"issue":"12","key":"2025122309411406300_bib7","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1182\/blood.2023023529","article-title":"NK cells with adhesion defects and reduced cytotoxic functions are associated with a poor prognosis in multiple myeloma","volume":"144","author":"Blanquart","year":"2024","journal-title":"Blood"},{"issue":"25","key":"2025122309411406300_bib8","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood.2024026455","article-title":"The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy","volume":"145","author":"Korst","year":"2025","journal-title":"Blood"},{"issue":"1","key":"2025122309411406300_bib9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"25","key":"2025122309411406300_bib10","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/bloodadvances.2017012732","article-title":"Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy","volume":"1","author":"Kini Bailur","year":"2017","journal-title":"Blood Adv"},{"issue":"2","key":"2025122309411406300_bib11","doi-asserted-by":"crossref","first-page":"296","DOI":"10.37349\/etat.2024.00219","article-title":"Emerging roles of type 1 innate lymphoid cells in tumour pathogenesis and cancer immunotherapy","volume":"5","author":"Verner","year":"2024","journal-title":"Explor Target Antitumor Ther"},{"issue":"1","key":"2025122309411406300_bib12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/imcb.12390","article-title":"Systemic administration of IL-33 induces a population of circulating KLRG1hi type 2 innate lymphoid cells and inhibits type 1 innate immunity against multiple myeloma","volume":"99","author":"Guillerey","year":"2021","journal-title":"Immunol Cell Biol"},{"issue":"2","key":"2025122309411406300_bib13","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3390\/jcm14020327","article-title":"From biology to clinical practice: the bone marrow microenvironment in multiple myeloma","volume":"14","author":"Fotiou","year":"2025","journal-title":"J Clin Med"},{"issue":"2","key":"2025122309411406300_bib14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nri3365","article-title":"Innate lymphoid cells--a proposal for uniform nomenclature","volume":"13","author":"Spits","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2025122309411406300_bib15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3390\/cancers17020263","article-title":"Multiple myeloma cells shift the fate of cytolytic ILC2s towards TIGIT-mediated cell death","volume":"17","author":"Drommi","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2025122309411406300_bib16","doi-asserted-by":"crossref","first-page":"101276","DOI":"10.1016\/j.smim.2019.04.004","article-title":"The pro- and anti-tumor role of ILC2s","volume":"41","author":"Trabanelli","year":"2019","journal-title":"Semin Immunol"},{"issue":"10","key":"2025122309411406300_bib17","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1158\/0008-5472.CAN-12-2357","article-title":"Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor \u03b1Su\/Fc fusion complex in syngeneic murine models of multiple myeloma","volume":"73","author":"Xu","year":"2013","journal-title":"Cancer Res"},{"issue":"1","key":"2025122309411406300_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/bloodadvances.2022007985","article-title":"Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15","volume":"7","author":"Fernandez","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2025122309411406300_bib19","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1038\/s41467-023-41562-6","article-title":"Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance","volume":"14","author":"Botta","year":"2023","journal-title":"Nat Commun"},{"issue":"10","key":"2025122309411406300_bib20","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1182\/bloodadvances.2019000953","article-title":"Myeloma cells induce the accumulation of activated CD94low NK cells by cell-to-cell contacts involving CD56 molecules","volume":"4","author":"Barberi","year":"2020","journal-title":"Blood Adv"},{"issue":"19","key":"2025122309411406300_bib21","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.3390\/cancers13194806","article-title":"Therapeutic potential of innate lymphoid cells for multiple myeloma therapy","volume":"13","author":"Szudy-Szczyrek","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2025122309411406300_bib22","doi-asserted-by":"crossref","first-page":"e881","DOI":"10.1097\/HS9.0000000000000881","article-title":"NK cell phenotype is associated with response and resistance to daratumumab in relapsed\/refractory multiple myeloma","volume":"7","author":"Verkleij","year":"2023","journal-title":"Hemasphere"},{"key":"2025122309411406300_bib23","doi-asserted-by":"crossref","first-page":"101668","DOI":"10.1016\/j.smim.2022.101668","article-title":"Myeloid derived suppressor cells in tumor microenvironment: interaction with innate lymphoid cells","volume":"61-64","author":"Tumino","year":"2022","journal-title":"Semin Immunol"},{"key":"2025122309411406300_bib24","doi-asserted-by":"crossref","first-page":"973836","DOI":"10.3389\/fonc.2022.973836","article-title":"Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche","volume":"12","author":"Solimando","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"2025122309411406300_bib25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s40164-024-00578-4","article-title":"Natural killer cell biology and therapy in multiple myeloma: challenges and opportunities","volume":"13","author":"Bisht","year":"2024","journal-title":"Exp Hematol Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6246\/2474199\/blooda_adv-2025-016659-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6246\/2474199\/blooda_adv-2025-016659-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T14:41:22Z","timestamp":1766500882000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/24\/6246\/547195\/Progressive-NK-cell-dysfunction-and-ILC-imbalance"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":25,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016659","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published-other":{"date-parts":[[2025,12,23]]},"published":{"date-parts":[[2025,12,10]]}}}